Written by Steve Blechman
25 April 2018

BREAKING-NEWS-SARMs-Crackdown-Slider

Breaking News! SARMs Crackdown!

SARMs Control Act of 2018

 

Senator Orrin Hatch (R-UT) and Senator Sheldon Whitehouse (D-RI) introduced a new bill to give the Drug Enforcement Administration (DEA) more authority to get SARMS (selective androgen receptor modulators) off the market. Senator Hatch has been a longtime proponent of the supplement industry. The bill was introduced in the U.S. Senate on the night of Tuesday, April 24, 2018 and is called the SARMs Control Act of 2018. The bill will give authority to the DEA to remove illegal SARM products sold over the counter and online as controlled substances.

           

SARMS are synthetic drugs that have negative effects to those of anabolic steroids,” Senator Hatch said in a statement released by his office, and appearing on the Senator’s web page. “Even though SARMs are not approved by the FDA for human use and pose the same safety risks as anabolic steroids, they have proliferated under a regime in which they are not subject to the same controls. The SARMs Control Act closes this loophole to ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

               

American consumers deserve to know if they’re buying seriously dangerous drugs slipped into everyday dietary supplements,” said Senator Whitehouse. “This bipartisan legislation will build on successful anti-designer steroids legislation we’ve already passed to help protect American consumers.”

           

Selective androgen receptor modulators (SARMS) are synthetic anabolic drugs made to bind with androgen receptors in specific tissues such as muscle. Most anabolic steroids bind with androgen receptors throughout the body, which causes many of their side effects. While they bind with receptors in the muscle, they also bind with receptors in other tissues that affect sperm quality, skin oiliness and blood pressure. SARMs that bind with androgen receptors in muscle have little or no effect in other tissues, so they produce fewer side effects. Testosterone therapy is extremely popular in middle-aged and older men. SARMs could provide the benefits of testosterone with fewer side effects (Asian Journal of Andrology, published online December 16, 2013).

           

SARMs will likely be a multibillion-dollar blockbuster drug in the pharmaceutical industry. The Food and Drug Administration (FDA) may eventually approve SARMs for the treatment of muscle-wasting diseases such as HIV, cancer, hypogonadism and sarcopenia (muscle loss with aging). SARMs provide anabolic benefits in the absence of androgenic effects on the prostate, hair and skin.

 

References:

Press Release, 4/24/18. Website of Senator Orrin Hatch (R-UT) https://www.hatch.senate.gov/public/index.cfm/releases?ID=F1021776-7B96-4244-A82E-23A9931C99CD

           

Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017;318(20):2004-2010. doi:10.1001/jama.2017.17069

           

Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl 2014; 16:256-61

 

DISCUSS THIS ARTICLE ON THE MD FORUM

 

 

 

FOLLOW MUSCULAR DEVELOPMENT ON:

FACEBOOK: MuscularDevelopment Magazine

TWITTER: @MuscularDevelop

INSTAGRAM: @MuscularDevelopment

YOUTUBE: http://bit.ly/2fvHgnZ